- Home
- ATPC vs XBIO Comparison
ATPC vs XBIO Comparison
Compare ATPC & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATPC
- XBIO
- Stock Information
- Founded
- ATPC 2016
- XBIO N/A
- Country
- ATPC Malaysia
- XBIO United States
- Employees
- ATPC N/A
- XBIO N/A
- Industry
- ATPC Medical/Nursing Services
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ATPC Health Care
- XBIO Health Care
- Exchange
- ATPC Nasdaq
- XBIO Nasdaq
- Market Cap
- ATPC 6.5M
- XBIO 6.3M
- IPO Year
- ATPC N/A
- XBIO N/A
- Fundamental
- Price
- ATPC $0.94
- XBIO $4.03
- Analyst Decision
- ATPC
- XBIO Hold
- Analyst Count
- ATPC 0
- XBIO 1
- Target Price
- ATPC N/A
- XBIO N/A
- AVG Volume (30 Days)
- ATPC 135.4K
- XBIO 4.8K
- Earning Date
- ATPC 03-04-2025
- XBIO 03-20-2025
- Dividend Yield
- ATPC N/A
- XBIO N/A
- EPS Growth
- ATPC N/A
- XBIO N/A
- EPS
- ATPC N/A
- XBIO N/A
- Revenue
- ATPC $1,354,042.00
- XBIO $2,523,427.00
- Revenue This Year
- ATPC N/A
- XBIO N/A
- Revenue Next Year
- ATPC N/A
- XBIO N/A
- P/E Ratio
- ATPC N/A
- XBIO N/A
- Revenue Growth
- ATPC N/A
- XBIO 7.15
- 52 Week Low
- ATPC $0.90
- XBIO $2.78
- 52 Week High
- ATPC $8.40
- XBIO $5.20
- Technical
- Relative Strength Index (RSI)
- ATPC 35.57
- XBIO 45.61
- Support Level
- ATPC $0.90
- XBIO $3.91
- Resistance Level
- ATPC $0.97
- XBIO $4.24
- Average True Range (ATR)
- ATPC 0.09
- XBIO 0.17
- MACD
- ATPC -0.03
- XBIO -0.01
- Stochastic Oscillator
- ATPC 7.06
- XBIO 28.93
About ATPC Agape ATP Corporation
Agape ATP Corp through its subsidiaries is engaged in providing health and wellness products and health solution advisory services. The principal activities of the company are to supply high-quality health and wellness products, including a supplement to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system in a body. Its product portfolio includes ATP1s Survivor Select, ATP2 Energized Mineral Concentrate, ATP3 Ionized Cal-Mag, ATP4 Omega Blend, AGN-Vege Fruit Fiber and Others.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.